Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to prevent the accumulation of substances ...

The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated ...

A low-intensity transcranial ultrasound stimulation device, developed by Sonomind SAS, was proven to be safe and effective in treating patients suffering from drug-resistant depression. The results of ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...

U.S. Health and Human Services Secretary Robert Kennedy made his first appearance May 14 before the Senate Health, Education, ...

Small interfering RNA (siRNA) gained another vote of confidence, albeit back end-loaded, from big pharma as privately held ...

Mirvie Inc. continues the development of precision medicine for pregnancy-related conditions with its Encompass blood test to ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and ...

The metabotropic nucleotide receptor P2Y14 shows strong potential as a therapeutic target against various inflammatory ...

Immunity is not a function most people particularly associate with the liver. But because of its connection to the gut, the ...

Apimeds Pharmaceuticals US Inc. (APUS), a subsidiary of Kospi-listed Inscobee Inc., said May 12 that it raised $13.5 million from its stock sale on the NYSE American exchange May 9 through an offering ...

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing ...